Why Mounjaro Causes Hypoglycemia When Combined With Insulin or Sulfonylureas: The Mechanism Explained

At a glance

• Incidence (SURPASS-6, tirzepatide plus basal insulin): Clinically significant hypoglycemia (<54 mg/dL) occurred in 15.0 to 19.5% of participants across tirzepatide dose groups, versus 3.7% with placebo plus insulin
• Incidence (SURPASS-2, tirzepatide plus background sulfonylurea sub-group): Hypoglycemia rates were approximately two- to three-fold higher in patients on concurrent sulfonylureas than in those on metformin alone
• Typical onset: Within the first 4 to 8 weeks of tirzepatide initiation or after each dose escalation
• First-line management: Pre-emptive dose reduction of the concurrent insulin or sulfonylurea before tirzepatide starts; self-monitoring of blood glucose (SMBG) at least twice daily during any titration period
• When to escalate: Any confirmed glucose <54 mg/dL, any episode requiring third-party assistance, or recurrent readings <70 mg/dL on two or more days in a week
• When to discontinue tirzepatide: Recurrent severe hypoglycemia unresponsive to complete sulfonylurea cessation or maximal basal insulin reduction

What Tirzepatide Actually Does to Glucose Physiology

Tirzepatide is not a straightforward GLP-1 receptor agonist. It is a single synthetic peptide that binds both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor with high affinity. That dual mechanism is what separates it pharmacologically from semaglutide or liraglutide, and it is directly relevant to why hypoglycemia risk in combination therapy is higher than many clinicians anticipate.

At the GLP-1 receptor, tirzepatide triggers pancreatic beta cells to release insulin in a glucose-dependent manner. "Glucose-dependent" sounds protective, and for monotherapy it largely is. But this phrase carries an important qualifier: the threshold at which the glucose-dependency switch turns off is not zero. Beta cells begin reducing their incretin-driven insulin secretion only once plasma glucose falls into the low-normal range, around 70 to 80 mg/dL. When exogenous insulin or a sulfonylurea is simultaneously driving glucose downward, the glucose-dependent brake on tirzepatide's insulinotropic effect may not engage quickly enough to prevent overshoot.

At the GIP receptor, tirzepatide produces a second wave of insulin secretion that is additive to the GLP-1 effect. GIP receptor signaling also potentiates beta-cell sensitivity to glucose, meaning the pancreas becomes more responsive to any given glucose concentration. In isolation, this is desirable. In the presence of a sulfonylurea or basal insulin, it means the pancreas is being sensitized to secrete more insulin at the same moment an external source of insulin activity is already lowering the glucose floor.

The net physiological result is triple-pathway glucose reduction: tirzepatide's GLP-1-driven insulin release, tirzepatide's GIP-driven beta-cell sensitization, and the glucose-independent action of either exogenous insulin or a sulfonylurea. None of these three pathways can detect or compensate for what the others are doing in real time.

Why Sulfonylureas Are Particularly Dangerous in This Combination

Sulfonylureas (glipizide, glimepiride, glyburide) close ATP-sensitive potassium channels on beta cells through a mechanism that is entirely independent of ambient glucose concentration. They force insulin secretion regardless of whether blood glucose is 200 mg/dL or 60 mg/dL. This is their core limitation as a drug class, and it becomes acutely relevant when tirzepatide is introduced.

When tirzepatide begins lowering postprandial glucose effectively, which can happen within the first two weeks of the 2.5 mg starting dose, the sulfonylurea does not scale back its insulin-forcing action. The patient is now experiencing strong GLP-1 and GIP-mediated insulin secretion on top of fixed, glucose-blind sulfonylurea-driven secretion. Counterregulatory glucagon release, the primary defense against hypoglycemia, is also blunted by GLP-1 receptor activation at the alpha cell, as demonstrated in mechanistic studies of GLP-1's effects on islet physiology. The patient therefore has impaired glucagon release, triple-pathway insulin excess, and no glucose-dependent off-switch on the sulfonylurea component.

The SURPASS-2 trial, which compared tirzepatide to semaglutide 1 mg in adults with type 2 diabetes on background metformin, did not mandate sulfonylurea co-administration. However, post-hoc analyses and the prescribing information confirm that hypoglycemia rates rise substantially when any insulin secretagogue is present. The FDA label recommends reducing the sulfonylurea dose or stopping it entirely when tirzepatide is initiated.

The practical guidance: consider reducing the sulfonylurea by 50% before the first tirzepatide injection. If HbA1c is already at or near target on the sulfonylurea, stopping it entirely at initiation is reasonable.

Why Insulin Combinations Carry a Different Risk Profile

Basal insulin and tirzepatide are increasingly used together, particularly in patients with longer-standing type 2 diabetes who have not achieved adequate glycemic control. The SURPASS-6 trial examined exactly this scenario, randomizing participants already on basal insulin to tirzepatide or placebo as an add-on. SURPASS-6 found that clinically significant hypoglycemia occurred in roughly 1 in 6 tirzepatide participants, with rates climbing further at the 10 mg and 15 mg doses.

The mechanism here differs from the sulfonylurea scenario in one key way: insulin's glucose-lowering effect is dose-titratable and relatively predictable, whereas a sulfonylurea's effect on any given patient varies with diet, renal function, and individual beta-cell reserve. With insulin, the prescriber has direct control over the glucose-independent insulin load. The SURPASS-6 protocol reduced basal insulin by 20% at randomization, and even with that pre-emptive reduction, hypoglycemia was still the most common adverse event.

When tirzepatide improves insulin sensitivity (through GIP-mediated effects on adipose tissue and skeletal muscle glucose uptake), the patient's effective insulin dose requirement drops. A basal insulin dose that was appropriate at baseline becomes relatively excessive within weeks. This is not a failure of the drug combination. It reflects tirzepatide working as intended, but the insulin regimen must be adjusted in parallel or hypoglycemia is predictable.

The American Diabetes Association's 2024 Standards of Care recommend proactive insulin dose reduction when adding any GLP-1 or dual incretin agonist, rather than reactive reduction after hypoglycemia has occurred.

Timing Within the Dose Escalation Schedule

Tirzepatide is initiated at 2.5 mg weekly and increased in 2.5 mg steps every four weeks to a maximum of 15 mg. Each dose increase represents a meaningful step-up in incretin receptor occupancy. Patients and prescribers sometimes manage the 2.5 mg starting dose without incident and conclude the combination is safe, then encounter hypoglycemia after the first or second escalation.

The risk window around each escalation is approximately two to four weeks. Insulin or sulfonylurea doses that were appropriate at one tirzepatide dose may need further reduction when the tirzepatide dose increases. SMBG frequency should increase around each escalation step: fasting glucose daily and two-hour postprandial glucose at least on three days per week is a reasonable monitoring minimum during titration.

Nocturnal hypoglycemia deserves specific attention. GLP-1 receptor agonism slows gastric emptying, redistributing postprandial glucose absorption across a longer window. This can suppress postprandial spikes while extending the duration of glucose-lowering activity into the overnight period, particularly when basal insulin is also active. Patients should check a bedtime glucose during each new titration period. A bedtime glucose consistently below 120 mg/dL in a patient on basal insulin is a signal to reduce the insulin dose before a nocturnal event occurs.

Identifying and Responding to Hypoglycemia in Real Time

Symptoms of hypoglycemia are the same regardless of mechanism: shakiness, sweating, rapid heartbeat, confusion, and hunger are the classic early signs. Patients on tirzepatide may notice that postprandial symptoms are muted because gastric emptying is slowed, which can give a false sense of glucose stability during meals. The hypoglycemia, when it occurs, may emerge one to two hours after the expected postprandial peak, rather than at the usual time.

For confirmed glucose <70 mg/dL (or symptomatic episodes without an available reading), the 15-15 rule applies: 15 grams of fast-acting carbohydrate (glucose tablets, 4 oz orange juice, regular soda), recheck in 15 minutes, repeat if still below 70 mg/dL. The American Diabetes Association position on hypoglycemia treatment is clear that glucose tablets or gel are preferred over food, as the fat content of food slows absorption. For severe hypoglycemia with altered consciousness, glucagon (nasal, auto-injector, or kit) is required. All patients on this combination should have a glucagon prescription filled before starting tirzepatide.

Dose Adjustment Reference

---

Frequently asked questions

›Can I keep taking my glimepiride when I start Mounjaro?

You may be able to continue it at a reduced dose, but starting Mounjaro without adjusting your glimepiride significantly raises your hypoglycemia risk. Most prescribers will cut the glimepiride dose by at least half before your first injection. If your blood sugar is already well controlled on glimepiride, stopping it entirely at the start of Mounjaro is often the safer choice. Discuss this with your prescriber before your first dose.

›My blood sugar has never gone low before. Why is it happening now that I added Mounjaro?

Mounjaro adds two separate insulin-stimulating effects (through the GLP-1 and GIP receptors) on top of whatever your existing medication was already doing. Your previous medication and your body had reached an equilibrium. Mounjaro shifts that equilibrium significantly, and the dose of your older drug that was correct before may now be too much. This is expected pharmacology, not a sign something is wrong with you.

›Is hypoglycemia from Mounjaro more likely at the beginning or after dose increases?

Both. The initial risk window is the first four to eight weeks. But each dose escalation (from 2.5 mg to 5 mg, then to 7.5 mg, and so on) creates a new risk period of two to four weeks. You should check your blood sugar more frequently around each step-up and contact your prescriber if readings are running lower than your usual range.

›What is a safe blood sugar to target while on Mounjaro plus insulin?

The general guidance from the ADA for non-pregnant adults with type 2 diabetes is a fasting glucose of 80 to 130 mg/dL and a two-hour postprandial glucose below 180 mg/dL. If you are on basal insulin with Mounjaro, fasting readings consistently below 100 mg/dL suggest your insulin dose may need to come down. Your specific targets should be confirmed with your prescriber.

›What should I do if I have a low blood sugar episode on this combination?

If you can check your glucose and it is below 70 mg/dL, take 15 grams of fast-acting carbohydrate (glucose tablets, 4 oz of juice, or regular soda), wait 15 minutes, and recheck. If you cannot check but you feel symptomatic, treat anyway. If the episode is severe or someone else has to help you, that is a medical event that needs same-day contact with your prescriber.

›Does Mounjaro cause hypoglycemia on its own, without insulin or a sulfonylurea?

Very rarely. On its own, tirzepatide's insulin-stimulating effect is glucose-dependent, meaning it reduces as blood sugar falls. In the SURPASS-1 trial (monotherapy), clinically significant hypoglycemia was reported in under 1% of participants. The meaningful hypoglycemia risk appears when glucose-independent agents (sulfonylureas or exogenous insulin) are combined with it.

›Do I need a glucagon kit if I am on Mounjaro plus insulin?

Yes. Any patient on a combination that includes exogenous insulin and a dual incretin agonist should have a glucagon rescue option available (nasal glucagon, an auto-injector kit, or a standard glucagon emergency kit). People you live with or spend significant time with should know where it is and how to use it.

›Will the hypoglycemia risk decrease as I stay on Mounjaro longer?

To some extent, yes, once the tirzepatide dose is stable and your concurrent insulin or sulfonylurea has been adjusted appropriately. The risk is highest during titration phases. However, if the concurrent medication has not been reduced adequately, the risk does not resolve on its own. Stability requires active dose management of the older medication, not just time.

›What symptoms should prompt me to call my doctor rather than just treating at home?

Call your prescriber or seek same-day care if you have a reading below 54 mg/dL, if you needed someone else's help during an episode, if you are having more than two low readings per week, or if your lows are happening overnight. Recurrent or severe hypoglycemia on this combination is a signal that your insulin or sulfonylurea dose needs formal reassessment.

›Can I eat more carbohydrates to prevent lows instead of reducing my other medication?

That approach adds calories and works against the blood sugar and weight management goals of tirzepatide. It is not a sustainable or recommended strategy. The appropriate fix is reducing the dose of the glucose-independent agent (insulin or sulfonylurea), not adjusting your diet to compensate for an excessive medication load.

References

1. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02188-7/fulltext
2. Rosenstock J, Frías JP, Rodbard HW, et al. Tirzepatide added to basal insulin versus continued basal insulin in type 2 diabetes (SURPASS-6): a randomised, open-label, phase 3a trial. N Engl J Med. 2023;389:597-609. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
4. Tirzepatide (Mounjaro) Prescribing Information. Eli Lilly and Company. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
5. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2024. Section 6: Glycemic Goals and Hypoglycemia. Diabetes Care. 2024;47(Suppl 1):S111-S125. https://diabetesjournals.org/care/article/47/Supplement_1/S111/153945/6-Glycemic-Goals-and-Hypoglycemia
6. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2024. Section 10: Cardiovascular Disease and Risk Management. Diabetes Care. 2024;47(Suppl 1):S158-S218. https://diabetesjournals.org/care/article/47/Supplement_1/S158/153954/10-Cardiovascular-Disease-and-Risk-Management
7. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000018/
8. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. https://diabetesjournals.org/diabetes/article/71/1/1/147647/GLP-1-and-Glucagon-Receptor-Dual-Agonism-for-Type